Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Schmid, J; Stojakovic, T; Zweiker, D; Scharnagl, H; Maderthaner, RD; Scherr, D; Maier, R; Schmidt, A; März, W; Binder, JS; Rainer, PP.
ST2 predicts survival in patients undergoing transcatheter aortic valve implantation.
Int J Cardiol. 2017; 244(23-24):87-92 Doi: 10.1016/j.ijcard.2017.06.066
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Rainer Peter

Schmid Johannes

Co-Autor*innen der Med Uni Graz

Binder Josepha Stephanie

Maier Robert

März Winfried

Scharnagl Hubert

Scherr Daniel

Schmidt Albrecht

Stojakovic Tatjana

Zweiker David

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

To assess soluble suppression of tumorigenicity 2 (sST2) serum concentrations and predict mortality in patients undergoing transcatheter aortic valve implantation (TAVI). We prospectively enrolled 74 patients with severe aortic stenosis (AS) who underwent TAVI and matched them to patients without aortic valve disease (n=74). AS patients underwent comprehensive echocardiographic and cardiac magnetic resonance imaging and laboratory examinations. sST2 levels were determined by enzyme-linked immunosorbent assay (ELISA), their association with post procedural mortality was investigated using logistic and Cox regression analyses, and the prognostic performance compared to established risk scores. AS patients had substantially higher sST2 levels than controls (39.5 vs. 17.8ng/mL, p<0.001). sST2 significantly correlated with left and right atrial sizes (r=0.25, p=0.033 and r=0.38, p=0.001). At one and two years, 10 (13.9%) and 18 (25%) patients had died, respectively. sST2 significantly predicted survival in uni- and multivariate Cox regression analyses in our cohort (p=0.005 and p=0.025). sST2 also predicted major adverse cardiovascular events (MACE, p=0.046). Adding sST2 to the established STS score improved prediction of two-year mortality in our cohort (ΔAUC=0.108; 95% CI -0.066-0.281; continuous NRI=0.778; 95% CI: 0.277-1.278 and IDI=0.141; 95% CI: 0.031-0.251), and a model containing both sST2 and the STS score had a negative predictive value of 96.1% and 86.3% regarding one and two-year mortality, respectively. sST2 is elevated in AS patients and a prognostic marker of survival after TAVI. Implementation of this marker in routine pre-TAVI workup may improve risk prediction and patient selection. Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Find related publications in this database (using NLM MeSH Indexing)

Aged -

Aged, 80 and over -

Aortic Valve Stenosis - blood

Aortic Valve Stenosis - mortality

Aortic Valve Stenosis - surgery

Biomarkers - blood

Cohort Studies -

Female -

Follow-Up Studies -

Humans -

Interleukin-1 Receptor-Like 1 Protein - blood

Male -

Predictive Value of Tests -

Prospective Studies -

Survival Rate - trends

Transcatheter Aortic Valve Replacement - mortality

Transcatheter Aortic Valve Replacement - trends

Find related publications in this database (Keywords)

Transcatheter aortic valve implantation (TAVI)

ST2

Biomarker

Risk stratification

Survival

© Med Uni Graz • Impressum